In CLL, approximately 3% of cases present mutations in this gene and most of them represent the gain-of-function L265P mutation that promotes the constitutive activation of the NF-kB (Puente et al., 2011; Landau et al., 2013; Mansouri et al., 2016; Ntoufa et al., 2016). This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.